These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30636670)

  • 21. Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease.
    Chhabra S; Jerkins JH; Conto JE; Zellner K; Shah NN; Hari PN; Hamadani M
    Leuk Lymphoma; 2020 Apr; 61(4):869-874. PubMed ID: 31762357
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dry Eye Disease: Focus on Prescription Therapy.
    Marshall LL; Hayslett RL
    Sr Care Pharm; 2023 Jun; 38(6):239-251. PubMed ID: 37231571
    [No Abstract]   [Full Text] [Related]  

  • 23. A review of the first anti-evaporative prescription treatment for dry eye disease: perfluorohexyloctane ophthalmic solution.
    Sheppard JD; Evans DG; Protzko EE
    Am J Manag Care; 2023 Nov; 29(14 Suppl):S251-S259. PubMed ID: 37930231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease.
    Locatelli EVT; Acuna KA; Betz J; Tovar AA; Galor A
    Cornea; 2024 Jan; 43(1):88-94. PubMed ID: 36853599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
    Godin MR; Gupta PK
    Clin Ophthalmol; 2017; 11():951-957. PubMed ID: 28579745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 6-Week, Prospective, Randomized, Single-Masked Study of Lifitegrast Ophthalmic Solution 5% Versus Thermal Pulsation Procedure for Treatment of Inflammatory Meibomian Gland Dysfunction.
    Tauber J
    Cornea; 2020 Apr; 39(4):403-407. PubMed ID: 31895884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety, adherence and discontinuation in varenicline solution nasal spray clinical trials for dry eye disease.
    Hauswirth SG; Kabat AG; Hemphill M; Somaiya K; Hendrix LH; Gibson AA
    J Comp Eff Res; 2023 Jun; 12(6):e220215. PubMed ID: 37096956
    [No Abstract]   [Full Text] [Related]  

  • 30. Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.
    Guimaraes de Souza R; Yu Z; Stern ME; Pflugfelder SC; de Paiva CS
    J Ocul Pharmacol Ther; 2018 Sep; 34(7):543-549. PubMed ID: 29958030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.
    Karpecki P; Barghout V; Schenkel B; Huynh L; Khanal A; Mitchell B; Yenikomshian M; Zanardo E; Matossian C
    BMC Ophthalmol; 2023 Nov; 23(1):443. PubMed ID: 37919692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
    Holland EJ; Whitley WO; Sall K; Lane SS; Raychaudhuri A; Zhang SY; Shojaei A
    Curr Med Res Opin; 2016 Oct; 32(10):1759-1765. PubMed ID: 27388660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dry Eye Syndrome Preferred Practice Pattern®.
    Akpek EK; Amescua G; Farid M; Garcia-Ferrer FJ; Lin A; Rhee MK; Varu DM; Musch DC; Dunn SP; Mah FS;
    Ophthalmology; 2019 Jan; 126(1):P286-P334. PubMed ID: 30366798
    [No Abstract]   [Full Text] [Related]  

  • 35. Lifitegrast Ophthalmic Solution 5% (Xiidra) for Dry Eye Disease.
    Patel J; Franko J
    Am Fam Physician; 2018 Jul; 98(2):119-120. PubMed ID: 30215991
    [No Abstract]   [Full Text] [Related]  

  • 36. Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):116-118. PubMed ID: 31381551
    [No Abstract]   [Full Text] [Related]  

  • 37. Eye amputation following lifitegrast treatment for ocular graft-versus-host disease: First case report.
    Ferrete T; Rocher F; Elmaleh V; Loschi M; Tieulie N; Baillif S; Martel A
    J Fr Ophtalmol; 2021 May; 44(5):652-657. PubMed ID: 33858697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sjogren's syndrome from the perspective of ophthalmology.
    Kuklinski E; Asbell PA
    Clin Immunol; 2017 Sep; 182():55-61. PubMed ID: 28476437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Topical 3% Diquafosol Ophthalmic Solution for the Treatment of Multifactorial Dry Eye Disease: Meta-Analysis of Randomized Clinical Trials.
    Nam K; Kim HJ; Yoo A
    Ophthalmic Res; 2019; 61(4):188-198. PubMed ID: 30654362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changing trends in the treatment of dry-eye disease.
    Dogru M; Nakamura M; Shimazaki J; Tsubota K
    Expert Opin Investig Drugs; 2013 Dec; 22(12):1581-601. PubMed ID: 24088227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.